We are pleased to inform you that our Subsidiary Company, M/s Deccan Remedies Limited, has received Approval from the Drugs Control Administration, Government of Andhra Pradesh granting ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gennex Laboratories' subsidiary, Deccan Remedies Limited, has received approvals from the Drugs Control Administration (DCA), Government of Andhra Pradesh, to manufacture four additional products under Form 25, valid until May 28, 2028. The approved products are Tapentadol Hydrochloride (Ph.Eur), Etoricoxib (IP), Nitazoxanide (TH), and Voriconazole (IP/EP/BP/USP). All products are cleared for both domestic sale and export purposes. Tapentadol is a pain-management drug, Etoricoxib is an anti-inflammatory, Nitazoxanide is an anti-parasitic, and Voriconazole is an antifungal — broadening the subsidiary's therapeutic portfolio across pain, inflammation, infection, and fungal treatment segments.
This regulatory approval expands the subsidiary's manufacturing portfolio in both domestic and export markets, potentially supporting future revenue growth. However, no immediate financial impact or order size is disclosed, so the effect on stock price is likely to be modest unless commercial traction follows.